Krisztián Zoltán Juhász

Krisztián Zoltán Juhász

Auto-generated profile, based on publicly available information

Krisztián Zoltán Juhász

University of Debrecen

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2026 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Open access
MCMatta Csaba
Matta Csaba
Roland Ádám TakácsRoland Ádám Takács
Roland Ádám Takács
EJEun-Jung Jin
Eun-Jung Jin
Zsuzsanna HelyesZsuzsanna Helyes
Zsuzsanna Helyes
ÁHÁdám István Horváth
Ádám István Horváth
Ali MobasheriAli Mobasheri
Ali Mobasheri
Transient receptor potential vanilloid 1 (TRPV1) has been pursued as a therapeutic target in osteoarthritis (OA) pain for over two decades. Both systemic antagonism and localized agonism advanced into clinical development, supported by mechanistic rationale and preclinical data. We critically appraise TRPV1-targeted drug development in OA, examining the biological basis of the target, translational trajectories of antagonist and agonist programs, and clinical trial outcomes that define the current landscape. Literature was identified through a PubMed search for peer‑reviewed articles on TRPV1 and OA over the past 5 years, followed by manual selection of key references. We review why systemic TRPV1 antagonists were abandoned, and why intra-articular TRPV1 agonists, despite expedited regulatory designations, failed to meet primary endpoints in Phase III trials. TRPV1-targeted therapy in OA has completed a full translational cycle without yielding regulatory approval. The mechanistic rationale remains valid; what failed was clinical translation. Key contributors include over-reliance on preclinical models poorly capturing central sensitization, lack of stratification by peripheral versus central pain phenotypes, and use of composite pain endpoints in phenotypically mixed populations. The TRPV1 experience offers lessons for peripheral analgesic development in OA: patient phenotyping and enrichment must precede pivotal trials.

21 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
PKPatrik Kovács
Patrik Kovács
PBPeter Brazda
Peter Brazda
Tibor HajdúTibor Hajdú
Tibor Hajdú
BHBoglárka Harsányi
Boglárka Harsányi
KJKrisztian Z Juhasz
Krisztian Z Juhasz
CMCsaba Matta
Csaba Matta
Background: Osteoarthritis is a degenerative joint disease characterized by progressive loss of articular cartilage and limited capacity for intrinsic repair. A major barrier to developing effective regenerative strategies is the incomplete understanding of the molecular mechanisms regulating chondrogenesis and cartilage maintenance. Cell surface proteins are key mediators of extracellular communication, adhesion, and signaling, yet the chondrogenic surfaceome remains incompletely mapped, with prior studies focusing primarily on mature or cytokine-activated chondrocytes. The aim of this study was to provide a temporal profile of the surfaceome during in vitro chondrogenic differentiation and to identify novel membrane proteins with potential roles in cartilage biology. Methods: We applied a sialoglycoprotein-targeted glycocapture strategy to selectively enrich plasma membrane proteins from chick embryonic limb bud-derived micromass cultures undergoing chondrogenesis. Enriched samples underwent high-resolution shotgun proteomic analysis, and differentially expressed candidates were validated by western blotting, immunocytochemistry, and transient gene silencing. Functional effects on extracellular matrix gene regulation were assessed by quantitative RT-PCR and matrix histochemistry. Results: This approach generated the first temporal surfaceome map of chondrogenic progenitors. Among identified candidates, two proteins not previously linked to chondrogenesis, podocalyxin (PODXL) and ciliary neurotrophic factor receptor (CNTFR), were detected at the plasma membrane and confirmed at the protein and transcript levels. Both proteins exhibited time-dependent downregulation during differentiation. Targeted knockdown revealed differential regulation of the fibrocartilage marker COL1A1 expression, indicating non-redundant roles in cell-matrix signaling and survival pathways. Single-cell transcriptomic meta-analysis confirmed expression of both proteins in discrete human articular chondrocyte subpopulations. Conclusions: This study expands the molecular framework of chondrogenesis, identifying PODXL and CNTFR as novel, temporally regulated surfaceome components with distinct roles in extracellular matrix signaling. These findings complement prior proteomic analyses of cytokine-activated mature articular chondrocytes and suggest new candidates for developmental cartilage biomarkers and therapeutic targets for osteoarthritis. Our results provide a resource for future cross-species surfaceome studies and highlight key pathways for further investigation into cartilage lineage specification and matrix adaptation. Plain English Summary: Osteoarthritis is the most common joint disease worldwide, causing pain, stiffness, and reduced mobility as the smooth cartilage that covers the ends of bones gradually breaks down. Cartilage has a very limited ability to heal itself, and there are currently no treatments that can stop or reverse the disease. Scientists are working on new ways to repair or replace damaged cartilage, but to do this effectively, they need to understand the molecular “language” that cartilage-forming cells use to develop and maintain healthy tissue. In this study, we examined the set of proteins that are present on the surface of cartilage-forming cells, known as the “surfaceome.” These surface proteins play important roles in how cells connect to their surroundings, receive signals, and work together to build the cartilage matrix. Using a method to selectively capture and analyze these proteins, we discovered two that had never been linked to cartilage development: podocalyxin and ciliary neurotrophic factor receptor. We found that these two proteins may have opposite effects on cartilage quality. Because they can be detected on the outside of cells, they could be developed into markers for early osteoarthritis detection or as targets for new therapies. Our findings open the door to new strategies for diagnosing and treating joint disease by focusing on cell-surface communication.

1 March 2026 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
ZWZhangzheng Wang
Zhangzheng Wang
KZKrisztián Juhász Zoltán
Krisztián Juhász Zoltán
CMCsaba Matta
Csaba Matta
LPLuca Paluska
Luca Paluska
AAAhmed Al-Mnaseer
Ahmed Al-Mnaseer
Laszlo DuczaLaszlo Ducza
Laszlo Ducza
Highlights: • Integrated bulk and single-cell transcriptomics identified potentially shared osteoarthritis (OA)–Alzheimer’s disease (AD) molecular programs. • An 18-gene shared up-regulated gene set (SUGS) was detected across OA and AD. • Fibrochondrocyte_1 emerged as a dominant-sender-like hub in OA cartilage. • Oligodendrocyte_3 emerged as a prominent-receiver-like hub in AD cortex. • Findings support a hypothesis-generating systems framework for OA–AD comorbidity.